Literature DB >> 9655488

Reevaluation of 3'Ekappa function in stage- and lineage-specific rearrangement and somatic hypermutation.

N van der Stoep1, J R Gorman, F W Alt.   

Abstract

Transgenic studies have led to the conclusion that the 3'Ekappa enhancer functions to suppress kappa variable region gene assembly in T lineage cells and in progenitor B cells and have also implicated 3'Ekappa as a critical element in promoting somatic hypermutation of kappa variable region genes. To assess the role of the endogenous 3'Ekappa, we assayed these processes in mice homozygous for mutations in which the 3'Ekappa sequences were deleted by the loxP/Cre method (3'Ekappa delta/delta mice). In contrast to transgenic findings, we found that deletion of the endogenous 3'Ekappa did not deregulate kappa gene rearrangement in T lineage cells or in pro-B cells. Furthermore, immunization of the 3'Ekappa delta/delta mice led to the generation of specific antibodies with mutation patterns typical of affinity maturation, showing that there is no absolute requirement for the 3'Ekappa with respect to somatic mutation of endogenous kappa genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655488     DOI: 10.1016/s1074-7613(00)80579-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  17 in total

1.  Induction of Ig light chain gene rearrangement in heavy chain-deficient B cells by activated Ras.

Authors:  A C Shaw; W Swat; L Davidson; F W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  A developmentally controlled competitive STAT5-PU.1 DNA binding mechanism regulates activity of the Ig κ E3' enhancer.

Authors:  Suchita Hodawadekar; Kyoungsook Park; Michael A Farrar; Michael L Atchison
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

3.  Elucidation of IgH intronic enhancer functions via germ-line deletion.

Authors:  Thomas Perlot; Frederick W Alt; Craig H Bassing; Heikyung Suh; Eric Pinaud
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

4.  Immunoglobulin kappa enhancers are differentially regulated at the level of chromatin structure.

Authors:  Barbara S Nikolajczyk; Sylvia H Sardi; Joseph R Tumang; Lisa M Ganley-Leal
Journal:  Mol Immunol       Date:  2007-03-26       Impact factor: 4.407

Review 5.  Related Mechanisms of Antibody Somatic Hypermutation and Class Switch Recombination.

Authors:  Joyce K Hwang; Frederick W Alt; Leng-Siew Yeap
Journal:  Microbiol Spectr       Date:  2015-02

6.  Comparison of identical and functional Igh alleles reveals a nonessential role for Eμ in somatic hypermutation and class-switch recombination.

Authors:  Fubin Li; Yi Yan; Joyce Pieretti; Danielle A Feldman; Laurel A Eckhardt
Journal:  J Immunol       Date:  2010-10-11       Impact factor: 5.422

7.  Recombination and transcription of the endogenous Ig heavy chain locus is effected by the Ig heavy chain intronic enhancer core region in the absence of the matrix attachment regions.

Authors:  E Sakai; A Bottaro; L Davidson; B P Sleckman; F W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  The Downstream Transcriptional Enhancer, Ed, positively regulates mouse Ig kappa gene expression and somatic hypermutation.

Authors:  Yougui Xiang; William T Garrard
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

9.  Transcription factor binding at Ig enhancers is linked to somatic hypermutation targeting.

Authors:  Ravi K Dinesh; Benjamin Barnhill; Anoj Ilanges; Lizhen Wu; Daniel A Michelson; Filip Senigl; Jukka Alinikula; Jeffrey Shabanowitz; Donald F Hunt; David G Schatz
Journal:  Eur J Immunol       Date:  2019-12-19       Impact factor: 5.532

10.  A cis-acting diversification activator both necessary and sufficient for AID-mediated hypermutation.

Authors:  Artem Blagodatski; Vera Batrak; Sabine Schmidl; Ulrike Schoetz; Randolph B Caldwell; Hiroshi Arakawa; Jean-Marie Buerstedde
Journal:  PLoS Genet       Date:  2009-01-09       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.